免疫检查点抑制剂同步放疗治疗老年食管鳞癌患者的临床疗效及安全性分析
摘要
癌方面的近期疗效和不良反应的差异。
关键词
全文:
PDF参考
[1]Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics
2020:GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries[J]. CA Cancer J
Clin,2021,71(3):209-249.
[2]Liu Q, Xia Y, Chen Y, et al. A study of concurrent
chemoradiotherapy with weekly docetaxel and cisplatin for
advanced esophageal squamous cell carcinoma with T4 and/or
M1 lymph node metastasis or locoregional recurrence [J].Radiat
Oncol,2020(15):75.
[3] 中国医师协会放射肿瘤治疗医师分会 , 中华医学会
放射肿瘤治疗学分会 , 中国抗癌协会肿瘤放射治疗专业委员
会 . 中国食管癌放射治疗指南 (2020 年版 )[J]. 国际肿瘤学杂
志 ,2020,47(11):641-655.
[4]Kato K, Cho BC, Takahashi M, et al. Nivolumab versus
chemotherapy in patients with advanced oesophageal squamous
cell carcinoma refractory or intolerant to previous chemotherapy
(ATTRACTION-3): a multicentre, randomised, open-label, phase
3 trial [J]. Lancet Oncol, 2019, 20:1506-1517.
[5]Huang J, Xu J, Chen Y, et al. Camrelizumab versus
investigator’s choice of chemotherapy as second-line therapy
for advanced or metastatic oesophageal squamous cell carcinoma
(ESCORT): a multicentre, randomised, open-label, phase 3 study
[J]. Lancet Oncol, 2020, 21:832-842.
[6]Shah MA, Kojima T, Hochhauser D, et al. Efficacy
and Safety of Pembrolizumab for Heavily Pretreated Patients
With Advanced, Metastatic Adenocarcinoma or Squamous Cell
Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
[J]. JAMA Oncol, 2019, 5:546-550.
[7] 张天 , 庞青松 . 局部晚期不可手术食管癌放射治疗研
究进展 [J]. 中华肿瘤防治杂志 ,2023,30(3):174-180.
[8]Sun JM, Shen L, Shah MA, Enzinger P, et al.
Pembrolizumab plus chemotherapy versus chemotherapy
alone for first-line treatment of advanced oesophageal cancer
(KEYNOTE-590): a randomised, placebo-controlled, phase 3
study [J]. Lancet, 2021, 398:759-771.
[9]Janjigian YY, Shitara K, Moehler M, et al. First-line
nivolumab plus chemotherapy versus chemotherapy alone for
advanced gastric, gastro-oesophageal junction, and oesophageal
adenocarcinoma (CheckMate 649): a randomised, open-label,
phase 3 trial [J]. Lancet, 2021, 398:27-40.
[10]Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs
Placebo Added to Chemotherapy on Survival and Progression-
Free Survival in Patients With Advanced or Metastatic Esophageal
Squamous Cell Carcinoma: The ESCORT-1st Randomized
Clinical Tria [J]l. JAMA, 2021, 326:916-925.
[11]Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in
combination with chemotherapy as first line treatment for locally
advanced or metastatic oesophageal squamous cell carcinoma
(ORIENT-15): multicentre, randomised, double blind, phase 3
trial [J]. BMJ, 2022:e068714.
[12]Wang Z-X, Cui C, Yao J, et al. Toripalimab plus
chemotherapy in treatment-na ve, advanced esophageal squamous
cell carcinoma (JUPITER-06): A multi-center phase 3 trial [J].
Cancer Cell, 2022, 40:277-288.e273.
[13]Yang Y, Pan J, Wang H, et al. Tislelizumab
plus chemotherapy as first-line treatment for recurrent or
metastatic nasopharyngeal cancer: A multicenter phase 3 trial
(RATIONALE-309) [J]. Cancer Cell, 2023, 41:1061-1072.e1064.
[14]Zhu Y, Wen J, Li Q, et al. Toripalimab combined with
definitive chemoradiotherapy in locally advanced oesophageal
squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2
trial [J]. Lancet Oncol, 2023, 24:371-382.
[15]Conroy T, Galais MP, Raoul JL, et al. Definitive
chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin
in patients with oesophageal cancer (PRODIGE5/ACCORD17):
final results of a randomised, phase 2/3 trial [J]. Lancet Oncol,
2014, 15:305-314.
[16]Zhang W, Yan C, Zhang T, et al. Addition of
camrelizumab to docetaxel, cisplatin, and radiation therapy
in patients with locally advanced esophageal squamous cell
carcinoma: a phase 1b study [J]. OncoImmunology, 2021, 10.
[17]Shen L, Kato K, Kim SB, et al. Tislelizumab Versus
Chemotherapy as Second-Line Treatment for Advanced or
Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-
302):A Randomized Phase III Study [J]. J Clin Oncol, 2022,
40:3065-3076.
[18] 陆 晓 , 陆 屸 , 金 振 军 等 . 信 迪 利 单 抗 联 合 化
疗 治 疗 晚 期 胃 癌 的 疗 效 及 安 全 性 [J]. 临 床 药 物 治 疗 杂
志 ,2023,21(11):47-51.
(1 摘要 Views, 3 PDF Downloads)
Refbacks
- 当前没有refback。